Novartis’s Sandoz Sets Out Post-Spinoff Growth Plan
Wall Street Journal
Novartis’s generics unit Sandoz forecast product pipeline net sales of $3 billion over the next five years and a core earnings margin of 18%-19% this year, lower than previously forecast due to inflation and costs.